These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 10417773)

  • 1. Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using (125)I-labeled anti-endoglin monoclonal antibodies.
    Tabata M; Kondo M; Haruta Y; Seon BK
    Int J Cancer; 1999 Aug; 82(5):737-42. PubMed ID: 10417773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
    Takahashi N; Haba A; Matsuno F; Seon BK
    Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.
    Seon BK; Matsuno F; Haruta Y; Kondo M; Barcos M
    Clin Cancer Res; 1997 Jul; 3(7):1031-44. PubMed ID: 9815781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies.
    Matsuno F; Haruta Y; Kondo M; Tsai H; Barcos M; Seon BK
    Clin Cancer Res; 1999 Feb; 5(2):371-82. PubMed ID: 10037187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective anti-angiogenic therapy of established tumors in mice by naked anti-human endoglin (CD105) antibody: differences in growth rate and therapeutic response between tumors growing at different sites.
    Tsujie M; Uneda S; Tsai H; Seon BK
    Int J Oncol; 2006 Nov; 29(5):1087-94. PubMed ID: 17016638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice.
    Tsujie M; Tsujie T; Toi H; Uneda S; Shiozaki K; Tsai H; Seon BK
    Int J Cancer; 2008 May; 122(10):2266-73. PubMed ID: 18224682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenesis and metastasis marker of human tumors.
    Seon BK; Takahashi N; Haba A; Matsuno F; Haruta Y; She XW; Harada N; Tsai H
    Rinsho Byori; 2001 Oct; 49(10):1005-13. PubMed ID: 11769465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells.
    She X; Matsuno F; Harada N; Tsai H; Seon BK
    Int J Cancer; 2004 Jan; 108(2):251-7. PubMed ID: 14639611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature.
    Uneda S; Toi H; Tsujie T; Tsujie M; Harada N; Tsai H; Seon BK
    Int J Cancer; 2009 Sep; 125(6):1446-53. PubMed ID: 19533687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiangiogenic chimeric anti-endoglin (CD105) antibody: pharmacokinetics and immunogenicity in nonhuman primates and effects of doxorubicin.
    Shiozaki K; Harada N; Greco WR; Haba A; Uneda S; Tsai H; Seon BK
    Cancer Immunol Immunother; 2006 Feb; 55(2):140-50. PubMed ID: 15856228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting angiogenesis for radioimmunotherapy with a
    Ehlerding EB; Lacognata S; Jiang D; Ferreira CA; Goel S; Hernandez R; Jeffery JJ; Theuer CP; Cai W
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):123-131. PubMed ID: 28821931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Facilitation of endoglin-targeting cancer therapy by development/utilization of a novel genetically engineered mouse model expressing humanized endoglin (CD105).
    Toi H; Tsujie M; Haruta Y; Fujita K; Duzen J; Seon BK
    Int J Cancer; 2015 Jan; 136(2):452-61. PubMed ID: 24866768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endoglin-targeted cancer therapy.
    Seon BK; Haba A; Matsuno F; Takahashi N; Tsujie M; She X; Harada N; Uneda S; Tsujie T; Toi H; Tsai H; Haruta Y
    Curr Drug Deliv; 2011 Jan; 8(1):135-43. PubMed ID: 21034418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy and dose-limiting toxicity of Auger-electron vs. beta emitters in radioimmunotherapy with internalizing antibodies: evaluation of 125I- vs. 131I-labeled CO17-1A in a human colorectal cancer model.
    Behr TM; Sgouros G; Vougiokas V; Memtsoudis S; Gratz S; Schmidberger H; Blumenthal RD; Goldenberg DM; Becker W
    Int J Cancer; 1998 May; 76(5):738-48. PubMed ID: 9610734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model.
    Fonsatti E; Jekunen AP; Kairemo KJ; Coral S; Snellman M; Nicotra MR; Natali PG; Altomonte M; Maio M
    Clin Cancer Res; 2000 May; 6(5):2037-43. PubMed ID: 10815930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct.
    Pavlinkova G; Booth BJ; Batra SK; Colcher D
    Clin Cancer Res; 1999 Sep; 5(9):2613-9. PubMed ID: 10499640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor vascular homing endgolin-targeted radioimmunotherapy in hepatocellular carcinoma.
    Duan CL; Hou GH; Liu YP; Liang T; Song J; Han JK; Zhang C
    Tumour Biol; 2014 Dec; 35(12):12205-15. PubMed ID: 25164610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy.
    Burrows FJ; Derbyshire EJ; Tazzari PL; Amlot P; Gazdar AF; King SW; Letarte M; Vitetta ES; Thorpe PE
    Clin Cancer Res; 1995 Dec; 1(12):1623-34. PubMed ID: 9815965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
    Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
    Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.